A Phase 2 interventional study of Levosimendan in Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction and Heart Failure With Normal Ejection Fraction, sponsored by Tenax Therapeutics, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Tenax Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing simendan in Heart Failure — 2 open to participants now, 2 under way, 2 of them phase 3. Simendan · Heart Failure.
Among the 32 studies testing simendan in Heart Failure, this one is the 26th largest by enrollment, is one of 3 that started in 2019, is one of 6 in phase 2, and was the 24th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →2 of the 32 studies testing simendan in Heart Failure are open now, in 2 countries. Recruiting first, the newest first:
Pr Bruno LEVY · Sites in France
Ages 18+
Chittagong Medical College · Sites in Bangladesh
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 12 · Phase 4 14
First in 2002; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 76 across the 32 interventional studies. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 32 have an industry lead sponsor. The 10 most frequent:
Tenax Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Tenax Therapeutics, Inc. has 6 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
1 of the studies testing simendan in Heart Failure that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020263Phase 3Pr Bruno LEVYEffect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock | 2027-02-03 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies testing simendan in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PH-HFpEF patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.
This study will enroll PH-HFpEF patients that have completed a controlled levosimendan study. These patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initial: A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion. Ongoing patients are transitioned to daily oral levosimendan (1mg capsules TID)
Drug: Levosimendan
Initial: A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for a weekly 24 hour infusion. Transioned to: Daily Levosimendan capsules (1 mg TID)
Clinical Safety
Number of Adverse Events per Patient Population
Time frame: Duration of study (for up to 2 years); Assessed at Weeks 3, 6, 12, 24, and 48 and Follow-Up Visit (termination visit).
Patients completing the Phase 2 HELP Study (TNX-LVO-04) were consented to open-label levosimendan.
| Milestone | Levosimendan Open-Label |
|---|---|
| Started | 35 |
| Completed | 16 |
| Not completed | 19 |
| Withdrew: Withdrawal by subject | 10 |
| Withdrew: Adverse event | 5 |
| Withdrew: Physician decision | 2 |
| Withdrew: Not provided | 2 |
Number of Adverse Events per Patient Population
| Participants | Levosimendan Open-Label |
|---|---|
| Clinical Safety | 33 |
Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levosimendan Open-Label | 2/35 (5.7%) | 24/35 (68.6%) | 15/35 (42.9%) |
| Event | Levosimendan Open-Label |
|---|---|
| Cardiac disordersCardiac disorders | 13/35 |
| Infections and infestationsInfections and infestations | 11/35 |
| Metabolism and nutrition disordersMetabolism and nutrition disorders | 6/35 |
| Renal and urinary disordersRenal and urinary disorders | 4/35 |
| Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 4/35 |
| Gastrointestinal disordersGastrointestinal disorders | 3/35 |
| General disordersGeneral disorders | 3/35 |
| Vascular disordersVascular disorders | 3/35 |
| Blood and lymphatic system disordersBlood and lymphatic system disorders | 2/35 |
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 2/35 |
| Event | Levosimendan Open-Label |
|---|---|
| Cardiac disordersCardiac disorders | 6/35 |
| Nervous system disordersNervous system disorders | 5/35 |
| Product issuesProduct Issues | 4/35 |
| Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 3/35 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 3/35 |
| General disordersGeneral disorders | 2/35 |
| Age, Continuous(years) | Levosimendan IV Transitioned to Levosimendan Capsules (1mg) |
|---|---|
| Mean | 68.3 ± 9.56 |
| Sex: Female, Male(Participants) | Levosimendan IV Transitioned to Levosimendan Capsules (1mg) |
|---|---|
| Female | 21 |
| Male | 14 |
| Race (NIH/OMB)(Participants) | Levosimendan IV Transitioned to Levosimendan Capsules (1mg) |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 31 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Levosimendan IV Transitioned to Levosimendan Capsules (1mg) |
|---|---|
| United States | 35 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Apr 2023, 48 months.
Results were first posted in Apr 2026, 2 years 11 months after primary completion.
Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 48 months is above that.
Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Simendan
Tenax Therapeutics, Inc.